Alexion Pharmaceuticals, Inc. logo
Alexion Pharmaceuticals, Inc. ALXN

Alexion Pharmaceuticals, Inc. Market Cap 2011-2026 | ALXN

As of February 10, 2026 Alexion Pharmaceuticals, Inc. has a market cap of $ 40.3 B


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Alexion Pharmaceuticals, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
33.6 B 22.4 B 27 B 27.4 B 28.7 B 31.1 B 36.3 B 31.7 B 18.2 B 13.7 B

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
36.3 B 13.7 B 27 B

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
Acer Therapeutics Acer Therapeutics
ACER
12.1 M - 2.71 % $ 14 M usaUSA
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
2.05 B - -15.15 % $ 60.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
4.09 M $ 0.83 2.17 % $ 4.53 M chinaChina
Acasti Pharma Acasti Pharma
ACST
40.7 M - 4.01 % $ 150 M canadaCanada
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
BioNTech SE BioNTech SE
BNTX
62.9 B $ 110.14 3.3 % $ 27.2 B germanyGermany
Adagene Adagene
ADAG
87.8 M $ 2.6 -1.12 % $ 146 M chinaChina
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
AlloVir AlloVir
ALVR
49 M - 4.14 % $ 49.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
664 K - -11.43 % $ 502 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
895 M $ 3.51 -0.52 % $ 8.45 B australiaAustralia
Applied Molecular Transport Applied Molecular Transport
AMTI
22.1 M - - $ 10.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
3.16 B $ 4.21 1.2 % $ 9.16 B israelIsrael
ARCA biopharma ARCA biopharma
ABIO
484 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
257 M $ 1.49 7.19 % $ 279 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.32 M - -45.71 % $ 1.2 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
538 M - -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
7.37 B $ 221.8 -0.16 % $ 5 B danmarkDanmark
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
71.4 M - 3.16 % $ 1.9 M usaUSA
Aptinyx Aptinyx
APTX
9.48 M - -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
60.4 M - -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
5.65 B - -6.81 % $ 3.04 B usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
4.13 M - 17.91 % $ 11.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
2.09 B $ 8.96 0.45 % $ 1.41 B britainBritain
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
Athira Pharma Athira Pharma
ATHA
16.2 M - - $ 269 M usaUSA
Athersys Athersys
ATHX
364 M - 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
172 M - 0.23 % $ 488 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
544 K - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
424 M $ 1.46 2.46 % $ 373 M britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
1.83 B $ 14.49 -0.24 % $ 4.48 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
AVROBIO AVROBIO
AVRO
56.3 M - 1083.1 % $ 745 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.72 M - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
15.8 M $ 2.35 -1.81 % $ 14.8 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
81.2 B - - $ 96.9 B britainBritain
Brickell Biotech Brickell Biotech
BBI
11.4 M - -5.38 % $ 6.06 M usaUSA